Loading…
← CockpitCompetitor Analysis › 002675.SZ Yantai Dongcheng Biochemicals Co., Ltd. Class AOpen in the cockpit ↗

Yantai Dongcheng Biochemicals Co., Ltd. Class A002675.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Yantai-based maker of iodine contrast media and radiopharmaceuticals used in medical imaging and nuclear medicine.

≈ A small Chinese GE Healthcare contrast-agent unitMomentum leader 86
Mkt cap
$1.59B
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$13.1M
20-day average traded
Fwd P/E
47.2×
forward earnings
ROIC−WACC
+1.4 pp
WACC 5.0%
Hurdle
+10 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥12.53
1D-1.2%
1W-4.4%
1M-2.6%
3M-5.9%
6M-0.2%
YTD-8.8%
1Y-18.6%
ATR %2.5%
52w lowhigh22.4% off high

What Yantai Dongcheng Biochemicals does

Yantai-based maker of iodine contrast media and radiopharmaceuticals used in medical imaging and nuclear medicine.

In one line: A small Chinese GE Healthcare contrast-agent unit.

Products and services

  • Iodine-based CT contrast agents
  • Radiopharmaceuticals (diagnostic isotopes)
  • Other specialty generics

Customers

  • Hospitals
  • Imaging centers

Where it sits in the supply chain

  • Pharmaceuticals
  • Diagnostics
  • Contrast media and radiopharmaceuticals

What could go right

  • Growing CT/MRI imaging volumes in China
  • Nuclear medicine adoption

What could go wrong

  • Isotope supply-chain dependence
  • Tender price pressure

Moat: narrow (regulatory licence, distribution). Licensed isotope handling and a national contrast-agent distribution network are hard to replicate.

Headquarters: Yantai, China · Employees: 2,583

Named competitors

  • GE Healthcare GEHC
  • Bracco Imaging private or unlisted
  • Beilu Pharmaceutical private or unlisted

Yantai Dongcheng Biochemicals at a glance

Size Yantai Dongcheng Biochemicals (002675.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.59B, the 1439th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.53 on 18 Nov 2026.

Performance Over six months the shares fell 0.2%, against -11.9% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue fell 4.2% over the last twelve months (peer median +6.6%); the operating margin is 14.8% (peer median 9.9%).

Valuation It trades at 47.2× forward earnings against a peer median of 25.6× (4th most expensive of 14).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.4 points above its cost of capital (5.0% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026002675.SZ 99Peer median 90
Six months, rebased to 100: Yantai Dongcheng Biochemicals against the median of its 20 peers (local-currency closes).

Yantai Dongcheng Biochemicals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.63BCN¥2.72BCN¥2.85BCN¥3.26BCN¥3.57B
Revenue growth—-5%-12%-9%—
Gross profitCN¥1.50BCN¥1.30BCN¥1.26BCN¥1.40BCN¥1.48B
EBITDAn/aCN¥572MCN¥456MCN¥529MCN¥680M
Net incomeCN¥210MCN¥196MCN¥184MCN¥210MCN¥307M
Free cash flowCN¥112MCN¥224M-CN¥163M-CN¥203MCN¥615M
Capital expenditureCN¥388MCN¥361MCN¥456MCN¥512MCN¥390M
Total debtCN¥1.49BCN¥2.61BCN¥2.26BCN¥1.72BCN¥1.84B

Quarterly statements and history in the cockpit →

Yantai Dongcheng Biochemicals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-20%0%+20%JUBLPHARMA600420002755301047002019ANURASASTRAZENSRPT0007661681600572603235300357298380INDGN600993CAPLIPOINT300723141080002675.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Yantai Dongcheng Biochemicals is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×60×JUBLPHARMA600420002755301047002019ANURAS1681600572300357INDGN600993CAPLIPOINT300723002675.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Yantai Dongcheng Biochemicals is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%600420002755301047ASTRAZENSRPT0007661681600572603235300357INDGN600993CAPLIPOINT300723002675.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Yantai Dongcheng Biochemicals is the large dot.

Yantai Dongcheng Biochemicals competitors and peer comparison

Head to head with its named competitors (002675.SZ vs GEHC)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Yantai Dongcheng Biochemicals 002675.SZ$1.59B0%-4%15%47.2×6.0%
GE HealthCare GEHC$37.8B+30%+7%14%15.6×5.0%

How Yantai Dongcheng Biochemicals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Yantai Dongcheng Biochemicals against its 20 peers (data as of 18 Nov 2026)
Measure002675.SZPeer medianRank in peer set
1-month return-2.6%-5.8%8th highest of 21
6-month return-0.2%-11.9%6th highest of 20
Distance from 52-week high-22.4%-36.7%8th highest of 21
Revenue growth (TTM)-4.2%+6.6%9th lowest of 20
Operating margin14.8%9.9%8th highest of 20
Forward P/E47.2×25.6×4th most expensive of 14
Growth the price implies (Req g, 7 yrs)6.0%12.1%7th least demanding of 15
Growth delivered (Del g)-4.3%+4.3%5th lowest of 15
Hurdle (Req g minus delivered)+10.3 pp+4.8 pp6th most demanding of 15
ROIC minus cost of capital+1.4 pp-1.0 pp9th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%47.2×6.0%-4.3%
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%29.0×n/an/a
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%12.6×-6.6%-5.6%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%57.4×12.8%-14.0%
Sino Biological 301047.SZChina$1.60B+27%+20%17%51.6×31.1%-15.1%
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%25.6×n/an/a
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%49.9×n/an/a
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%n/a42.4%+23.0%
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%n/a-6.8%+32.4%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%16.0×-6.1%+1.9%
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%n/a-4.9%+0.2%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%n/an/an/a
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
LigaChem Biosciences 141080.KSSouth Korea$1.48B-72%-55%-324%n/an/an/a

Questions

Who are Yantai Dongcheng Biochemicals's main competitors?
Named competitors: GE Healthcare (GEHC), Bracco Imaging (private or unlisted), Beilu Pharmaceutical (private or unlisted). The cockpit's measured peer set (industry) also includes Jubilant Pharmova (JUBLPHARMA.NS), Shanghai Shyndec Pharmaceutical (600420.SS), Beijing Aosaikang Pharmaceutical (002755.SZ), Sino Biological (301047.SZ), Yifan Pharmaceutical (002019.SZ), Anupam Rasayan India (ANURAS.NS).
Is Yantai Dongcheng Biochemicals expensive compared with its peers?
On forward p/e it trades at 47.2× against a peer median of 25.6×, 4th most expensive of 14 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Yantai Dongcheng Biochemicals stock performed?
Over six months to 18 Nov 2026 the shares returned -0.2% against -11.9% for the median peer; over one year -18.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.